Hong Kong
· Delayed Price · Currency is HKD CSPC Pharmaceutical Group Statistics
Total Valuation
CSPC Pharmaceutical Group has a market cap or net worth of HKD 54.57 billion. The enterprise value is 45.11 billion.
| Market Cap | 54.57B |
| Enterprise Value | 45.11B |
Important Dates
The next estimated earnings date is Wednesday, November 20, 2024.
| Earnings Date | Nov 20, 2024 |
| Ex-Dividend Date | Oct 31, 2024 |
Share Statistics
CSPC Pharmaceutical Group has 11.71 billion shares outstanding. The number of shares has decreased by -0.51% in one year.
| Shares Outstanding | 11.71B |
| Shares Change (YoY) | -0.51% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 24.23% |
| Owned by Institutions (%) | 31.95% |
| Float | 8.12B |
Valuation Ratios
The trailing PE ratio is 8.67 and the forward PE ratio is 7.76. CSPC Pharmaceutical Group's PEG ratio is 0.95.
| PE Ratio | 8.67 |
| Forward PE | 7.76 |
| PS Ratio | 1.62 |
| PB Ratio | 1.47 |
| P/FCF Ratio | n/a |
| PEG Ratio | 0.95 |
Enterprise Valuation
| EV / Earnings | 7.08 |
| EV / Sales | 1.33 |
| EV / EBITDA | 5.10 |
| EV / EBIT | 5.88 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.54, with a Debt / Equity ratio of 1.07.
| Current Ratio | 2.54 |
| Quick Ratio | 2.20 |
| Debt / Equity | 1.07 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | n/a |
| Interest Coverage | 194.41 |
Financial Efficiency
Return on equity (ROE) is 17.34% and return on invested capital (ROIC) is 12.75%.
| Return on Equity (ROE) | 17.34% |
| Return on Assets (ROA) | 9.86% |
| Return on Capital (ROIC) | 12.75% |
| Revenue Per Employee | 1.68M |
| Profits Per Employee | 313,706 |
| Employee Count | 23,500 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.92 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.46% in the last 52 weeks. The beta is 0.68, so CSPC Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -18.46% |
| 50-Day Moving Average | 5.72 |
| 200-Day Moving Average | 6.29 |
| Relative Strength Index (RSI) | 30.44 |
| Average Volume (20 Days) | 80,250,517 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CSPC Pharmaceutical Group had revenue of HKD 34.01 billion and earned 6.37 billion in profits. Earnings per share was 0.54.
| Revenue | 34.01B |
| Gross Profit | 24.28B |
| Operating Income | 7.76B |
| Pretax Income | 8.07B |
| Net Income | 6.37B |
| EBITDA | 8.76B |
| EBIT | 7.76B |
| Earnings Per Share (EPS) | 0.54 |
Balance Sheet
The company has 11.62 billion in cash and 417.84 million in debt, giving a net cash position of 11.20 billion or 0.96 per share.
| Cash & Cash Equivalents | 11.62B |
| Total Debt | 417.84M |
| Net Cash | 11.20B |
| Net Cash Per Share | 0.96 |
| Equity (Book Value) | 39.19B |
| Book Value Per Share | 3.17 |
| Working Capital | 17.23B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 71.38%, with operating and profit margins of 22.82% and 18.72%.
| Gross Margin | 71.38% |
| Operating Margin | 22.82% |
| Pretax Margin | 23.72% |
| Profit Margin | 18.72% |
| EBITDA Margin | 25.75% |
| EBIT Margin | 22.82% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.32, which amounts to a dividend yield of 6.71%.
| Dividend Per Share | 0.32 |
| Dividend Yield | 6.71% |
| Dividend Growth (YoY) | 33.33% |
| Years of Dividend Growth | 9 |
| Payout Ratio | n/a |
| Buyback Yield | 0.51% |
| Shareholder Yield | 7.22% |
| Earnings Yield | 11.54% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 15, 2020. It was a forward split with a ratio of 1.6.
| Last Split Date | Oct 15, 2020 |
| Split Type | Forward |
| Split Ratio | 1.6 |